Literature DB >> 8097925

Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.

P Omvik1, P Lund-Johansen, H Haugland.   

Abstract

Beta-blockers with less cardiodepressive effect than traditional nonselective beta(1+2)-blocking agents could be useful in the treatment of hypertension, provided the reduction in blood pressure was satisfactory. Epanolol, a selective beta 1-receptor blocker with intrinsic sympathomimetic activity, induced a fall in intraarterial pressure of 8% at rest sitting and 11% during 100 W bicycle exercise after the first dose of 200 mg in 12 patients with essential hypertension. Heart rate, stroke index, and cardiac index initially fell by 14%, 11%, and 23%, respectively. The total peripheral resistance index increased by 21% after 2 hours, and then reverted towards the pretreatment level. After 10 months of epanolol treatment (mean 300 mg/day), the reduction in arterial pressure was 5% at rest and 10% during exercise. Cardiac index and heart rate were still reduced 14-21%, while total peripheral resistance was unchanged or slightly increased (2-10%). Twenty-four hour ambulatory blood pressure was higher on epanolol (300 mg/day) than on atenolol (150 mg/day) treatment (137/97 vs. 128/91 mmHg). Thus, the achieved blood pressure reduction induced by epanolol was moderate, while other characteristics of beta-receptor blockade, in particular, the reduction of heart rate and cardiac output, were maintained. This suggests that the compound may be useful for other cardiovascular disorders, e.g., angina pectoris in patients without hypertension or cardiac arrhythmia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097925     DOI: 10.1007/bf00878321

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  14 in total

1.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

2.  The paradox of beta-adrenergic blockade in hypertension.

Authors:  E D Frohlich; R C Tarazi; H P Dustan; I H Page
Journal:  Circulation       Date:  1968-03       Impact factor: 29.690

3.  Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol.

Authors:  P Lund-Johansen
Journal:  Eur Heart J       Date:  1983-07       Impact factor: 29.983

4.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

5.  Comparison of the immediate effects of two beta-blocking drugs: a nonselective and a cardioselective with modest ISA in exercise-induced angina.

Authors:  G M Berkenboom; T Ibrahim; M Abramowicz; S G Degre
Journal:  Cardiology       Date:  1987       Impact factor: 1.869

Review 6.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

7.  Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

8.  Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292.

Authors:  H J Smith; S E Halliday; D C Earl; D Stribling
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

9.  Physical performance and muscle metabolism during beta-adrenergic blockade in man.

Authors:  P Kaiser
Journal:  Acta Physiol Scand Suppl       Date:  1984

10.  Circadian antihypertensive profile of carvedilol (BM 14190).

Authors:  W Meyer-Sabellek; K L Schulte; A Distler; R Gotzen
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  3 in total

Review 1.  Do partial agonist beta-blockers have improved clinical utility?

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

2.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

3.  Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease.

Authors:  E H Venneker; W J Remme; D C van Hoogenhuyze; X H Krauss; G L Bartels; D A Kruijssen; C J Storm; D van Schelven
Journal:  Cardiovasc Drugs Ther       Date:  1994-04       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.